S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma

PURPOSE: Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patien...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Onco Targets Ther
Autores principales: Katono, Ken, Sato, Yuichi, Kobayashi, Makoto, Nagashio, Ryo, Ryuge, Shinichiro, Igawa, Satoshi, Ichinoe, Masaaki, Murakumo, Yoshiki, Saegusa, Makoto, Masuda, Noriyuki
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679695/
https://ncbi.nlm.nih.gov/pubmed/29138580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S145072
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares